Home
>
US Stocks
>
Cara Therapeutics Inc
Cara Therapeutics Inc
CARA

Cara Therapeutics Inc

$13.163.66%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
13.47
Today Low/High
13.1 / 13.55
52 Week Low/High
$11.22 / $29.65
P/E ratio
76.27
Market Cap
$637.14M

Company Details

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA™ has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis, primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
Organisation
Cara Therapeutics Inc
Headquaters
Stamford, Connecticut, US
Employees
80
Industry
Health Technology
CEO
Derek Chalmers

Discover more

Frequently Asked Questions

What is Cara Therapeutics Inc share price today

Can Indians buy Cara Therapeutics Inc shares?

How can I buy Cara Therapeutics Inc shares from India?

Can Fractional shares of Cara Therapeutics Inc be purchased?

What are the documents required to start investing in Cara Therapeutics Inc stocks?

We are a SEBI registered investement advisor